FDA wants new warning for weight loss drugs over possible risk of vision loss

The FDA has asked manufacturers of GLP-1 drugs including Ozempic, Wegovy, Mounjaro and Zepbound to add a label warning about a rare eye condition that can cause severe vision loss, a risk also under review in Europe. The agency's request covers semaglutide-based therapies used for diabetes and weight loss, and regulators said patients on the ingredient should be monitored more closely. The move matters because GLP-1 drugs are among the fastest-growing product classes in pharma, and a safety warning could affect prescribing and labeling across the category. Watch for manufacturer responses and whether European regulators follow with their own label guidance.